Compare Brown-Forman Corporation Class B (BF.B) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brown-Forman Corporation Class B vs Zoetis Inc — how do they compare? Brown-Forman Corporation Class B trades at $28.01, while Zoetis Inc trades at $73.7 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while Brown-Forman Corporation Class B pays none, and Brown-Forman Corporation Class B is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| BF.B | ZTS | |
|---|---|---|
Sector | Consumer Staples | Health |
52-Week High | $31.26 | $156.76 |
52-Week Low | $22.80 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BF.B trades at $27.92, down 0.96% with mixed technical signals showing bullish moving averages but neutral oscillators. The stock has demonstrated earnings momentum with three consecutive quarterly beats, though analyst coverage remains divided with a 25% buy rating. Recent price action shows consolidation around the $28 pivot point level.
The outlook remains cautiously optimistic given strong recent earnings performance, though limited analyst coverage and divided sentiment suggest moderate risk. Upside potential exists if earnings momentum continues, while downside risks include market volatility and potential execution challenges in maintaining growth trajectory.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
